Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11480751 | 0.89 | GABRA1 (0.36) | GABRA1GABRB2L3MBTL1TAAR1ALDH1A1 | |
| SCHEMBL910032 | 0.84 | DAO (0.38) | GABRA1GABRB2TAAR1 | |
| SCHEMBL25425763 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2MGLLMAPTL3MBTL1 | |
| SCHEMBL29390847 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2MGLLMAPTL3MBTL1 | |
| SCHEMBL36294 | 0.81 | GABRA1 (0.58) | GABRA1GABRB2MGLLMAPTL3MBTL1 | |
| SCHEMBL791151 | 0.79 | GABRA1 (0.48) | GABRA1GABRB2MGLLMAPTL3MBTL1 | |
| SCHEMBL28460037 | 0.79 | GABRA1 (0.48) | GABRA1GABRB2MGLLMAPTL3MBTL1 | |
| SCHEMBL811980 | 0.78 | TAAR1 (0.52) | MAPTTAAR1ALDH1A1GAAKDM4E | |
| SCHEMBL7687789 | 0.78 | APOBEC3G (0.43) | L3MBTL1TAAR1ALDH1A1GAA | |
| SCHEMBL956458 | 0.78 | ALDH1A1 (0.52) | GABRA1GABRB2MGLLMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964544-A1 | Sensitive skin perfumes | Takasago International Corporation (JP) | 2008-09-03 | — | — | EP | claimed |
| EP-1964542-A1 | Sensitive skin perfumes | Takasago International Corporation (JP) | 2008-09-03 | — | — | EP | claimed |
| CN-106278965-B | Aryl alkyl asymmetry over cure class compound and its synthetic method and application | 华东师范大学 | 2018-02-23 | — | — | CN | disclosed |
| CN-106278965-A | Aryl alkyl asymmetric over cure compounds and synthetic method thereof and application | 华东师范大学 | 2017-01-04 | — | — | CN | disclosed |
| CN-102319184-B | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| CN-101969920-B | Parakeratosis inhibitor, pore shrinking agent or agent for preventing or improving rough skin, and composition for external use on the skin containing the same | SHISEIDO CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-1880711-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-01-23 | — | — | EP | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-5208152-A | CATALYSTS OF DIELS-ALDER REACTIONS, METHODS AND CATALYSTS THEREFOR | THE SCRIPPS RESEARCH INSTITUTE (US) | 1993-05-04 | — | — | US | disclosed |
| WO-1991005804-A1 | CATALYSIS OF DIELS-ALDER REACTIONS, METHODS AND CATALYSTS THEREFOR | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1991-05-02 | — | — | WO | disclosed |
| US-4438277-A | Hydronaphthalene derivatives | SANKYO COMPANY, LIMITED (JP) | 1984-03-20 | — | — | US | disclosed |
| US-4361515-A | Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use | SANKYO COMPANY, LIMITED (JP) | 1982-11-30 | — | — | US | disclosed |
| US-4042472-A | Electrolytic process for 7-methoxy-3-exomethylenecepham compounds | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | GABRA1 3368/4885GABRB2 3758/4885MGLL 1523/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | GABRA1 4400/4885GABRB2 3764/4885MGLL 3636/4885 |
| US-20120165409-A1 | WRINKLE-IMPROVING AGENT | AAAS, GLA, COL14A1 | GABRA1 1620/4885GABRB2 899/4885MGLL 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.